RVL Pharmaceuticals plc – NASDAQ:OSMT
RVL Pharmaceuticals stock price today
RVL Pharmaceuticals stock price monthly change
RVL Pharmaceuticals stock price quarterly change
RVL Pharmaceuticals stock price yearly change
RVL Pharmaceuticals key metrics
Market Cap | 110.17M |
Enterprise value | 92.97M |
P/E | -0.69 |
EV/Sales | 1.28 |
EV/EBITDA | -1.00 |
Price/Sales | 0.96 |
Price/Book | 1.27 |
PEG ratio | N/A |
EPS | -0.70 |
Revenue | 36.91M |
EBITDA | -36.33M |
Income | -68.26M |
Revenue Q/Q | -2.24% |
Revenue Y/Y | 5.63% |
Profit margin | -150.53% |
Oper. margin | -90.17% |
Gross margin | 54.9% |
EBIT margin | -90.17% |
EBITDA margin | -98.42% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRVL Pharmaceuticals stock price history
RVL Pharmaceuticals stock forecast
RVL Pharmaceuticals financial statements
| Sep 2022 | 10.02M | -14.44M | -144.14% |
|---|---|---|---|
| Dec 2022 | 9.80M | -18.31M | -186.8% |
| Mar 2023 | 8.83M | -11.61M | -131.48% |
| Jun 2023 | 8.25M | -23.88M | -289.28% |
| 2020-08-11 | -0.12 | -0.22 |
|---|---|---|
| 2021-05-13 | -0.23 | -0.15 |
| 2021-08-16 | -0.15 | -0.15 |
| 2021-11-15 | -0.31 | -0.28 |
| Sep 2022 | 155355000 | 86.80M | 55.88% |
|---|---|---|---|
| Dec 2022 | 128510000 | 77.41M | 60.24% |
| Mar 2023 | 111108000 | 71.10M | 64% |
| Jun 2023 | 85404000 | 69.07M | 80.88% |
| Sep 2022 | -10.09M | 231K | 42.20M |
|---|---|---|---|
| Dec 2022 | -16.43M | -172K | 1.39M |
| Mar 2023 | -5.81M | -1.22M | -4.86M |
| Jun 2023 | -12.06M | -959K | -460K |
RVL Pharmaceuticals alternative data
| Aug 2023 | 302 |
|---|---|
| Sep 2023 | 302 |
| Oct 2023 | 302 |
| Nov 2023 | 302 |
| Dec 2023 | 302 |
| Jan 2024 | 302 |
| Feb 2024 | 302 |
| Mar 2024 | 302 |
| Apr 2024 | 302 |
| May 2024 | 302 |
| Jun 2024 | 302 |
| Jul 2024 | 302 |
RVL Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Dec 2021 | 93800 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | SCHAUB JAMES officer: EVP and .. | Ordinary Shares | 93,800 | $1.07 | $100,366 | ||
Purchase | BURGSTAHLER DAVID F director, 10 percent owner | Ordinary Shares | 1,250,000 | N/A | N/A | ||
Purchase | VENKATARAMAN SRIRAM director, 10 percent owner | Ordinary Shares | 1,250,000 | N/A | N/A | ||
Purchase | AVISTA CAPITAL PARTNERS III GP, L.P. 10 percent owner | Ordinary Shares | 1,250,000 | N/A | N/A | ||
Purchase | ALTCHEM LTD 10 percent owner | Ordinary Shares | 1,250,000 | N/A | N/A | ||
Purchase | HARSAUL FOUNDATION 10 percent owner | Ordinary Shares | 1,250,000 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q3 2021 15 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Q2 2021 16 Aug 2021 | Q2 2021 Earnings Call Transcript |
| Q1 2021 13 May 2021 | Q1 2021 Earnings Call Transcript |
| Q4 2020 30 Mar 2021 | Q4 2020 Earnings Call Transcript |
-
What's the price of RVL Pharmaceuticals stock today?
One share of RVL Pharmaceuticals stock can currently be purchased for approximately $1.11.
-
When is RVL Pharmaceuticals's next earnings date?
Unfortunately, RVL Pharmaceuticals's (OSMT) next earnings date is currently unknown.
-
Does RVL Pharmaceuticals pay dividends?
No, RVL Pharmaceuticals does not pay dividends.
-
How much money does RVL Pharmaceuticals make?
RVL Pharmaceuticals has a market capitalization of 110.17M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 184.1% to 49.72M US dollars. RVL Pharmaceuticals made a loss 51.69M US dollars in net income (profit) last year or -$0.28 on an earnings per share basis.
-
What is RVL Pharmaceuticals's stock symbol?
RVL Pharmaceuticals plc is traded on the NASDAQ under the ticker symbol "OSMT".
-
What is RVL Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of RVL Pharmaceuticals?
Shares of RVL Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are RVL Pharmaceuticals's key executives?
RVL Pharmaceuticals's management team includes the following people:
- Mr. Brian A. Markison Chairman, Pres & Chief Executive Officer(age: 66, pay: $1,410,000)
- Mr. James D. Schaub Executive Vice President & Chief Operating Officer(age: 43, pay: $668,300)
- Mr. Christopher A. Klein Gen. Counsel & Sec.(age: 60, pay: $653,260)
- Dr. Tina Marie deVries Executive Vice President of R&D(age: 64, pay: $653,260)
-
How many employees does RVL Pharmaceuticals have?
As Jul 2024, RVL Pharmaceuticals employs 302 workers.
-
When RVL Pharmaceuticals went public?
RVL Pharmaceuticals plc is publicly traded company for more then 6 years since IPO on 12 Oct 2018.
-
What is RVL Pharmaceuticals's official website?
The official website for RVL Pharmaceuticals is osmotica.com.
-
Where are RVL Pharmaceuticals's headquarters?
RVL Pharmaceuticals is headquartered at 400 Crossing Blvd, Bridgewater, NEW JERSEY.
-
How can i contact RVL Pharmaceuticals?
RVL Pharmaceuticals's mailing address is 400 Crossing Blvd, Bridgewater, NEW JERSEY and company can be reached via phone at +1 908 809 1300.
RVL Pharmaceuticals company profile:
RVL Pharmaceuticals plc
osmotica.comNASDAQ
302
Biotechnology
Healthcare
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Bridgewater, NEW JERSEY 08807
CIK: 0001739426
:
:
